Equity

9 Months Ended

Sep. 30, 2011

Equity [Abstract]

Equity

10. Equity

										Accumulated
					Other					Other									Non-
	Common Stock				Paid-In		Retained			Comprehensive			Treasury Stock						Controlling
($ and shares in millions)	Shares		Par Value		Capital		Earnings			Loss			Shares			Cost			Interests			Total
Balance January 1, 2010		3,563	$	1,781	$	39,683	$	41,405		$	(2,767	)		454		$	(21,044	)	$	2,427		$	61,485
Net income attributable to Merck & Co., Inc.		—		—		—		1,393			—			—			—			—			1,393
Cash dividends declared on common stock		—		—		—		(3,552	)		—			—			—			—			(3,552	)
Mandatory conversion of 6% convertible preferred stock		4		2		132		—			—			—			—			—			134
Treasury stock shares purchased		—		—		—		—			—			47			(1,593	)		—			(1,593	)
Share-based compensation plans and other		10		5		742		—			—			(4	)		129			—			876
Other comprehensive loss		—		—		—		—			(723	)		—			—			—			(723	)
Net income attributable to noncontrolling interests		—		—		—		—			—			—			—			89			89
Distributions attributable to noncontrolling interests		—		—		—		—			—			—			—			(61	)		(61	)
Balance September 30, 2010		3,577	$	1,788	$	40,557	$	39,246		$	(3,490	)		497		$	(22,508	)	$	2,455		$	58,048
Balance January 1, 2011		3,577	$	1,788	$	40,701	$	37,536		$	(3,216	)		495		$	(22,433	)	$	2,429		$	56,805
Net income attributable to Merck & Co., Inc.		—		—		—		4,760			—			—			—			—			4,760
Cash dividends declared on common stock		—		—		—		(3,533	)		—			—			—			—			(3,533	)
Treasury stock shares purchased		—		—		—		—			—			41			(1,359	)		—			(1,359	)
Share-based compensation plans and other		—		—		16		—			—			(11	)		377			—			393
Other comprehensive income		—		—		—		—			503			—			—			—			503
Net income attributable to noncontrolling interests		—		—		—		—			—			—			—			89			89
Distributions attributable to noncontrolling interests		—		—		—		—			—			—			—			(62	)		(62	)
Balance September 30, 2011		3,577	$	1,788	$	40,717	$	38,763		$	(2,713	)		525		$	(23,415	)	$	2,456		$	57,596

     In connection with the 1998 restructuring of Astra Merck Inc., the Company assumed $2.4 billion par value preferred stock with a dividend rate of 5% per annum, which is carried by KBI and included in Noncontrolling interests on the Consolidated Balance Sheet. If AstraZeneca exercises the Shares Option (see Note 8), this preferred stock obligation will be settled.

     The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows:

													Accumulated
							Employee			Cumulative			Other
							Benefit			Translation			Comprehensive
($ in millions)	Derivatives			Investments			Plans			Adjustment			Income (Loss)
Balance January 1, 2010	$	(42	)	$	33		$	(2,469	)	$	(289	)	$	(2,767	)
Other comprehensive income (loss)		30			17			142			(912	)		(723	)
Balance at September 30, 2010	$	(12	)	$	50		$	(2,327	)	$	(1,201	)	$	(3,490	)
Balance January 1, 2011	$	41		$	31		$	(2,043	)	$	(1,245	)	$	(3,216	)
Other comprehensive income (loss)		(77	)		(11	)		59			532			503
Balance at September 30, 2011	$	(36	)	$	20		$	(1,984	)	$	(713	)	$	(2,713	)

     Comprehensive income (loss) was $1.8 billion and $1.5 billion for the three months ended September 30, 2011 and 2010, respectively, and was $5.3 billion and $669 million for the nine months ended September 30, 2011 and 2010, respectively.

     Included in the cumulative translation adjustment are pretax (losses) gains of $(84) million and $221 million for the first nine months of 2011 and 2010, respectively, from euro-denominated notes which have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Also included in cumulative translation adjustment are pretax gains (losses) of approximately $393 million and $(963) million for the first nine months of 2011 and 2010, respectively, relating to translation impacts of intangible assets recorded in conjunction with the Merger.